Beyond the hormone: Insulin as an autoimmune target in type 1 diabetes

Endocrine Reviews

Volumn 32, Issue 5, 2011, Pages 623-669

  Brezar, Vedran ^a,b   Carel, Jean Claude ^b,c   Boitard, Christian ^a,b,d   Mallone, Roberto ^a,b,d  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BHT 3021; C PEPTIDE; DNA VACCINE; HORMONE; INSULIN ZINC SUSPENSION; NBI 6024; PI C19 A3 PEPTIDE; PLACEBO; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE MARKER; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; THYMUS; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED NOD; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PROINSULIN; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RATS, INBRED BB; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 80052146396     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2011-0010     Document Type: Review

References (422)

1. Maslow AH 1966 The psychology of science: a reconnaissance. Richmond, CA: Maurice Bassett Publishing
2. Gepts W 1965 Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619-633
3. Bottazzo GF, Florin-Christensen A, Doniach D 1974 Isletcell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2:1279-1283
4. Huang SW, Maclaren NK 1976 Insulin-dependent diabetes: a disease of autoaggression. Science 192:64-66
5. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL 1983 Insulin antibodies in insulindependent diabetics before insulin treatment. Science 222: 1337-1339
6. Atkinson MA, Maclaren NK 1993 Islet cell autoantigens in insulin-dependent diabetes. J Clin Invest 92:1608-1616
7. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO 1993 Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366:72-75
8. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y 1980 Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29:1-13
9. Delovitch TL, Singh B 1997 The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727-738
10. Atkinson MA, Leiter EH 1999 The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604
11. Greiner DL, Malkani S, Kanaitsuka T, Bortell R, Doukas J, Rigby M, Whalen B, Stevens LA, Moss J, Mordes JP, Rossini AA 1997 The T cell marker RT6 in a rat model of autoimmune diabetes. Adv Exp Med Biol 419:209-216
12. Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA, Wallace JE, Welsh RM 1991 Induction of type I diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats. Science 254:1010-1013
13. von Herrath MG, Guerder S, Lewicki H, Flavell RA, Oldstone MB 1995 Coexpression of B7-1 and viral ("self") transgenes in pancreatic β cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 3:727-738
14. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA, Uematsu S, Akira S, Hengartner H, Zinkernagel RM 2005 Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11:138-145
15. Casares S, Hurtado A, McEvoy RC, Sarukhan A, von Boehmer H, Brumeanu TD 2002 Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 3:383-391
16. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tîrgovi{thorn}te C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC 2003 Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511
17. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM, Clayton DG, Todd JA 2006 A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 38:617-619
18. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, Ionescu-Tîrgoviote C, Simmonds MJ, Heward JM, Gough SC, Dunger DB, Wicker LS, Clayton DG 2007 Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857-864
19. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, Clayton DG, Wicker LS, Todd JA 2007 Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 39:1074-1082
20. Nejentsev S, Howson JM, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, Hulme J, Maier LM, Smyth D, Bailey R, Cooper JD, Ribas G, Campbell RD, Clayton DG, Todd JA 2007 Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450:887-892
21. Concannon P, Rich SS, Nepom GT 2009 Genetics of type 1A diabetes. N Engl J Med 360:1646-1654
22. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D 2002 Projection of an immunological self shadow within the thymus by the aire protein. Science 298: 1395-1401
23. Jones EY, Fugger L, Strominger JL, Siebold C 2006 MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 6:271-282
24. Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, Teyton L 2000 A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288:505-511
25. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, Unanue ER, Fremont DH 2000 Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 12:699- 710
26. Lee KH, Wucherpfennig KW, Wiley DC 2001 Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2:501-507
27. Nepom GT, Kwok WW 1998 Molecular basis for HLA-DQ associations with IDDM. Diabetes 47:1177-1184
28. Ettinger RA, Liu AW, Nepom GT, Kwok WW 1998 Exceptional stability of the HLA-DQA1*0102/DQB1*0602 α β protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. J Immunol 161:6439-6445
29. Bougnères P 2006 Editorial: genotypic and phenotypic complexity at the insulin variable number of tandem repeats locus. J Clin Endocrinol Metab 91:4246-4249
30. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F 1995 Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 9:284-292
31. Pugliese A, Zeller M, Fernandez Jr A, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, PatelDD 1997 The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 15:293-297
32. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C 1997 Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 15: 289-292
33. Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM, Blanche S, Bartunkova J, Vilmer E, Fischer A, Le Deist F, Rieux-Laucat F 2004 Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 351:1409-1418
34. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH 2010 Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+) CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59:407-415
35. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J 2003 Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 52:1052-1055
36. Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T 2008 Concordance for islet autoimmunityamongmonozygotic twins. N Engl J Med 359:2849-2850
37. Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R 1992 Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. BMJ 304:1020-1022
38. Kondrashova A, Viskari H, Kulmala P, Romanov A, Ilonen J, Hyöty H, Knip M 2007 Signs of β-cell autoimmunity in nondiabetic schoolchildren: a comparison between Russian Karelia with a low incidence of type 1 diabetes and Finland with a high incidence rate. Diabetes Care 30:95-100
39. Hermann R, Knip M, Veijola R, Simell O, Laine AP, Akerblom HK, Groop PH, Forsblom C, Pettersson-Fernholm K, Ilonen J 2003 Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes-indication of an increased environmental pressure? Diabetologia 46:420-425
40. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, Gale EA 2004 The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 364:1699-1700
41. Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG, Harrison LC 2008 The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 31:1546-1549
42. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC 2004 Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661-1667
43. Menser MA, Forrest JM, Bransby RD 1978 Rubella infection and diabetes mellitus. Lancet 1:57-60
44. Yoon JW, Austin M, Onodera T, Notkins AL 1979 Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300:1173-1179
45. Lönnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, Savola K, Muona P, Simell T, Koskela P, Hyöty H 2000 Enterovirus infection as a risk factor for β-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 49:1314-1318
46. 46. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, Couper JJ, Tait BD, Colman PG, Harrison LC 2000 Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 49:1319-1324
47. Hyöty H, Taylor KW 2002 The role of viruses in human diabetes. Diabetologia 45:1353-1361
48. Serreze DV, Ottendorfer EW, Ellis TM, Gauntt CJ, Atkinson MA 2000 Acceleration of type 1 diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T-cells in pancreatic islets. Diabetes 49:708-711
49. Stene LC, Oikarinen S, Hyöty H, Barriga KJ, Norris JM, Klingensmith G, Hutton JC, Erlich HA, Eisenbarth GS, Rewers M 2010 Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 59:3174-3180
50. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Muda AO, Prato SD, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P 2007 Coxsackie B4virus infection ofβ cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104:5115-5120
51. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG 2009 The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52:1143-1151
52. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H 1991 Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319-331
53. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK 1994 Cellular immunity to a determinantcommonto glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 94:2125-2129
54. Honeyman MC, Stone NL, Harrison LC 1998 T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med 4:231-239
55. Honeyman MC, Stone NL, Falk BA, Nepom G, Harrison LC 2010 Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. J Immunol 184:2204-2210
56. Bach JF 2002 The effect of infections on susceptibility to autoimmune and allergic diseases. NEngl J Med 347:911-920
57. Filippi CM, von Herrath MG 2008 Viral trigger for type 1 diabetes: pros and cons. Diabetes 57:2863-2871
58. Bougnères P, Valleron AJ 2008 Causes of early-onset type 1 diabetes: toward data-driven environmental approaches. J Exp Med 205:2953-2957
59. TEDDY Study Group 2008 The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 1150:1-13
60. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT 2000 Neonatal β-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 49:1-7
61. Mathis D, Vence L, Benoist C 2001 β-Cell death during progression to diabetes. Nature 414:792-798
62. Turley S, Poirot L, Hattori M, Benoist C, Mathis D 2003 Physiological β cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198:1527-1537
63. Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B 2000 β-Cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 49:1325-1333
64. Gagnerault MC, Luan JJ, Lotton C, Lepault F 2002 Pancreatic lymph nodes are required for priming of β cell reactive T cells in NOD mice. J Exp Med 196:369-377
65. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F, Marrack P, Mahata SK, Kappler JW, Haskins K 2010 Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 11:225-231
66. Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B 2011 Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol 186:3831-3835
67. Narendran P, Neale AM, Lee BH, Ngui K, Steptoe RJ, Morahan G, Madsen O, Dromey JA, Jensen KP, Harrison LC 2006 Proinsulin is encoded by an RNAsplice variant in human blood myeloid cells. Proc Natl Acad Sci USA 103: 16430-16435
68. Garcia CA, Prabakar KR, Diez J, Cao ZA, Allende G, Zeller M, Dogra R, Mendez A, Rosenkranz E, Dahl U, Ricordi C, Hanahan D, Pugliese A 2005 Dendritic cells in human thymus and periphery display a proinsulin epitope in a transcription-dependent, capture-independent fashion. J Immunol 175:2111-2122
69. Deltour L, Leduque P, Blume N, Madsen O, Dubois P, Jami J, Bucchini D 1993 Differential expression of the two nonallelic proinsulin genes in the developing mouse embryo. Proc Natl Acad Sci USA 90:527-531
70. Schechter R, Beju D, Gaffney T, Schaefer F, Whetsell L 1996 Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res 736:16-27
71. Thébault-Baumont K, Dubois-Laforgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, Morin J, Laloux V, Lehuen A, Carel JC, Jami J, Muller S, Boitard C 2003 Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 111:851-857
72. Faideau B, Lotton C, Lucas B, Tardivel I, Elliott JF, Boitard C, Carel JC 2006 Tolerance to proinsulin-2 is due to radioresistant thymic cells. J Immunol 177:53-60
73. Chentoufi AA, Polychronakos C 2002 Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2locus may predispose to diabetes. Diabetes 51:1383-1390
74. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS 2003 Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci USA 100:10376-10381
75. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS 2005 Prime role for an insulin epitope in the development of type 1 diabetes in NODmice. Nature 435: 220-223
76. Daniel D, Gill RG, Schloot N, Wegmann D 1995 Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 25:1056-1062
77. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway Jr CA 1999 Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 5:1026-1031
78. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW 2006 Responses against islet antigens in NODmice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 116:3258-3265
79. Krishnamurthy B, Mariana L, Gellert SA, Colman PG, Harrison LC, Lew AM, Santamaria P, Thomas HE, Kay TW 2008 Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J Immunol 180:4458-4464
80. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P 2000 Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406: 739-742
81. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H 2003 Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med 197:1635-1644
82. Kubosaki A, Gross S, Miura J, Saeki K, Zhu M, Nakamura S, Hendriks W, Notkins AL 2004 Targeted disruption of the IA-2β gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice. Diabetes 53:1684-1691
83. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV 1993 Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366:69-72
84. Solimena M, Dirkx Jr R, Hermel JM, Pleasic-Williams S, Shapiro JA, Caron L, Rabin DU 1996 ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J 15:2102-2114
85. Rose NR, Witebsky E 1956 Studies on organ specificity. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunol 76: 417-427
86. Moriyama H, Wen L, Abiru N, Liu E, Yu L, Miao D, Gianani R, Wong FS, Eisenbarth GS 2002 Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci USA 99:5539-5544
87. Homo-Delarche F, Boitard C 1996 Autoimmune diabetes: the role of the islets of Langerhans. Immunol Today 17: 456-460
88. Foulis AK, McGill M, Farquharson MA 1991 Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-γ containing cells. J Pathol 165:97-103
89. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG 2009 Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155:173-181
90. Diez J, Park Y, Zeller M, Brown D, Garza D, Ricordi C, Hutton J, Eisenbarth GS, Pugliese A 2001 Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 50: 895-900
91. Dogra RS, Vaidyanathan P, Prabakar KR, Marshall KE, Hutton JC, Pugliese A 2006 Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. Diabetologia 49:953-957
92. Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, Jensen KP, Kay TW, Rossjohn J, Falk BA, Nepom GT, Purcell AW 2005 The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 202:1191-1197
93. Calderon B, Suri A, Miller MJ, Unanue ER 2008 Dendritic cells in islets of Langerhans constitutively present β cellderived peptides bound to their class II MHC molecules. Proc Natl Acad Sci USA 105:6121-6126
94. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY 2002 Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851-860
95. Donath MY, Shoelson SE 2011 Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107
96. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Holländer GA, Piali L 2002 β-Cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 8: 1414-1420
97. Berman JS, Center DM 1987 Chemotactic activity of porcine insulin for human T lymphocytes in vitro. J Immunol 138:2100-2103
98. Leiter EH 1987 Murine macrophages and pancreatic β cells. Chemotactic properties of insulin and β-cytostatic action of interleukin 1. J Exp Med 166:1174-1179
99. Liu HM, Potter EL 1962 Development of the human pancreas. Arch Pathol 74:439-452
100. Jansen A, Voorbij HA, Jeucken PH, Bruining GJ, Hooijkaas H, Drexhage HA 1993 An immunohistochemical study on organized lymphoid cell infiltrates in fetal and neonatal pancreases. A comparison with similar infiltrates found in the pancreas of a diabetic infant. Autoimmunity 15:31-38
101. Papaccio G, Baccari GC, Strate C, Linn T 1994 Pancreatic duct inflammatory infiltration in the nonobese diabetic (NOD) mouse. J Anat 185:465-470
102. Jolicoeur C, Hanahan D, Smith KM 1994 T-cell tolerance toward a transgenic β-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc Natl Acad Sci USA 91:6707-6711
103. Throsby M, Homo-Delarche F, Chevenne D, Goya R, Dardenne M, Pleau JM 1998 Pancreatic hormone expression in the murine thymus: localization in dendritic cells and macrophages. Endocrinology 139:2399-2406
104. Derbinski J, Schulte A, Kyewski B, Klein L 2001 Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2:1032-1039
105. Garcia CA, Prabakar KR, Diez J, Cao ZA, Allende G, Zeller M, Dogra R, Mendez A, Rosenkranz E, Dahl U, Ricordi C, Hanahan D, Pugliese A 2005 Dendritic cells in human thymus and periphery display a proinsulin epitope in a transcription-dependent, capture-independent fashion. J Immunol 175:2111-2122
106. Chentoufi AA, Palumbo M, Polychronakos C 2004 Proinsulin expression by Hassall's corpuscles in the mouse thymus. Diabetes 53:354-359
107. Carlsén M, Cilio CM 2008 Evidence for de novo expression of thymic insulin by peripheral bone marrow-derived cells. Scand J Immunol 68:67-74
108. Martin-Pagola A, Pileggi A, Zahr E, Vendrame F, Damaris Molano R, Snowhite I, Ricordi C, Eisenbarth GS, Nakayama M, Pugliese A 2009 Insulin 2 gene (Ins2) transcription by NOD bone marrow-derived cells does not influence autoimmune diabetes development in NOD-Ins2 knockout mice. Scand J Immunol 70:439-446
109. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo MJ, Redondo M, Diez J, Eisenbarth GS, Patel DD, Ricordi C 2001 Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 107:555-564
110. Gotter J, Brors B, Hergenhahn M, Kyewski B 2004 Med-ullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199:155-166
111. Kyewski B, Derbinski J 2004 Self-representation in the thymus: an extended view. Nat Rev Immunol 4:688-698
112. Pugliese A, Diez J 2002 Lymphoid organs contain diverse cells expressing self-molecules. Nat Immunol 3:335-336
113. Pietropaolo M, Giannoukakis N, Trucco M 2002 Cellular environment and freedom of gene expression. Nat Immunol 3:335
114. Mathis D, Benoist C 2009 Aire. Annu Rev Immunol 27: 287-312
115. Yano M, Kuroda N, Han H, Meguro-Horike M, Nishikawa Y, Kiyonari H, Maemura K, Yanagawa Y, Obata K, Takahashi S, Ikawa T, Satoh R, Kawamoto H, Mouri Y, Matsumoto M 2008 Aire controls the differentiation program of thymic epithelial cells in the medulla for the establishment of self-tolerance. J Exp Med 205:2827-2838
116. Derbinski J, Gäbler J, Brors B, Tierling S, Jonnakuty S, Hergenhahn M, Peltonen L, Walter J, Kyewski B 2005 Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 202:33-45
117. Derbinski J, Pinto S, Rösch S, Hexel K, Kyewski B 2008 Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism. Proc Natl Acad Sci USA 105:657-662
118. Levi D, Polychronakos C 2009 Regulation of insulin gene expression by cytokines and cell-cell interactions in mouse medullary thymic epithelial cells. Diabetologia 52:2151-2158
119. Palumbo MO, Levi D, Chentoufi AA, Polychronakos C 2006 Isolation and characterization of proinsulin-producing medullary thymic epithelial cell clones. Diabetes 55: 2595-2601
120. Zhu M, Chin RK, Tumanov AV, Liu X, Fu YX 2007 Lymphotoxin β receptor is required for the migration and selection of autoreactive T cells in thymic medulla. J Immunol 179:8069-8075
121. Villaseñor J, Besse W, Benoist C, Mathis D 2008 Ectopic expression of peripheral-tissue antigens in the thymic epithelium: probabilistic, monoallelic, misinitiated. Proc Natl Acad Sci USA 105:15854-15859
122. Johnnidis JB, Venanzi ES, Taxman DJ, Ting JP, Benoist CO, Mathis DJ 2005 Chromosomal clustering of genes controlled by the aire transcription factor. Proc Natl Acad Sci USA 102:7233-7238
123. Peterson P, Org T, Rebane A 2008 Transcriptional regulation by AIRE: molecular mechanisms of central tolerance. Nat Rev Immunol 8:948-957
124. Noso S, Kataoka K, Kawabata Y, Babaya N, Hiromine Y, Yamaji K, Fujisawa T, Aramata S, Kudo T, Takahashi S, Ikegami H 2010 Insulin transactivator MafA regulates intrathymic expression of insulin and affects susceptibility to type 1 diabetes. Diabetes 59:2579-2587
125. Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS 2008 Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321:843-847
126. Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A, Farr AG, Tung KS, Engelhard VH 2010 Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med 207:681-688
127. Fletcher AL, Lukacs-Kornek V, Reynoso ED, Pinner SE, Bellemare-Pelletier A, Curry MS, Collier AR, Boyd RL, Turley SJ 2010 Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med 207:689-697
128. Poliani PL, Kisand K, Marrella V, Ravanini M, Notarangelo LD, Villa A, Peterson P, Facchetti F 2010 Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am J Pathol 176:1104-1112
129. Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, Albert PR, Collier AR, Turley SJ, Fathman CG, Creusot RJ 2009 Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10:1026-1033
130. Jarchum I, DiLorenzo TP 2010 Ins2 deficiency augments spontaneous HLA-A*0201-restricted T cell responses to insulin. J Immunol 184:658-665
131. Fan Y, Rudert WA, Grupillo M, He J, Sisino G, Trucco M 2009 Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 28:2812-2824
132. Hernández-Sánchez C, Mansilla A, de la Rosa EJ, de Pablo F 2006 Proinsulin in development: new roles for an ancient prohormone. Diabetologia 49:1142-1150
133. WuQ, Brown MR 2006 Signaling and function of insulinlike peptides in insects. Annu Rev Entomol 51:1-24
134. Mayer JP, Zhang F, DiMarchi RD 2007 Insulin structure and function. Biopolymers 88:687-713
135. De Meyts P 2004 Insulin and its receptor: structure, function and evolution. Bio Essays 26:1351-1362
136. Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA 1972 Three-dimensional atomic structure of insulin and its relationship to activity. Diabetes 21:492-505
137. Conlon JM 2001 Evolution of the insulin molecule: insights into structure-activity and phylogenetic relationships. Peptides 22:1183-1193
138. Wentworth BM, Rhodes C, Schnetzler B, Gross DJ, Halban PA, Villa-Komaroff L 1992 The ratio of mouse insulin I:insulin II does not reflect that of the corresponding preproinsulin mRNAs. Mol Cell Endocrinol 86:177-186
139. Steiner DF 2004 The proinsulin C-peptide-a multirole model. Exp Diabesity Res 5:7-14
140. Halban PA 2004 Cellular sources of new pancreaticβ cells and therapeutic implications for regenerative medicine. Nat Cell Biol 6:1021-1025
141. Lernmark A, Molenaar JL, van Beers WA, Yamaguchi Y, Nagataki S, Ludvigsson J, Maclaren NK 1991 The Fourth International Serum Exchange Workshop to standardize cytoplasmic islet cell antibodies. The Immunology and Diabetes Workshops and Participating Laboratories. Diabetologia 34:534-535
142. Greenbaum CJ, Palmer JP, Nagataki S, Yamaguchi Y, Molenaar JL, Van Beers WA, MacLaren NK, Lernmark A 1992 Improved specificity of ICA assays in the Fourth International Immunology of Diabetes serum exchange workshop. Diabetes 41:1570-1574
143. Atkinson MA, Maclaren NK 1993 Islet cell autoantigens in insulin-dependent diabetes. J Clin Invest 92:1608-1616
144. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E 1995 Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 155:5419-5426
145. Böhmer K, Keilacker H, Kuglin B, Hübinger A, Bertrams J, Gries FA, Kolb H 1991 Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies. Diabetologia 34:830-834
146. Bingley PJ, Bonifacio E, Mueller PW 2003 Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 52:1128-1136
147. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ 2008 Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846-852
148. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS 2007 Immunological responses to exogenous insulin. Endocr Rev 28:625-652
149. Vardi P, Dib SA, Tuttleman M, Connelly JE, Grinbergs M, Radizabeh A, Riley WJ, Maclaren NK, Eisenbarth GS, Soeldner JS 1987 Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type I diabetes mellitus. Diabetes 36:1286-1291
150. Wilkin T, Nicholson S, Casey C 1985 A micro enzymelinked immunosorbent assay for insulin antibodies in serum. J Immunol Methods 76:185-194
151. Wilkin TJ 1990 Insulin autoantibodies as markers for type I diabetes. Endocr Rev 11:92-104
152. Sodoyez-Goffaux F, Koch M, Dozio N, Brandenburg D, Sodoyez JC 1988 Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assays of insulin antibodies. Diabetologia 31:694-702
153. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H 1992 Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 74:1040-1044
154. Liu E, Eisenbarth GS 2007 Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 125:120-126
155. Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA 1997 Anovel micro-assay for insulin autoantibodies. J Autoimmun 10:473-478
156. Naserke HE, Dozio N, Ziegler AG, Bonifacio E 1998 Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay. Diabetologia 41:681-683
157. Roll U, Christie MR, Füchtenbusch M, Payton MA, Hawkes CJ, Ziegler AG 1996 Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood. Diabetes 45:967-973
158. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS 2000 Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 97:1701-1706
159. Williams AJ, Norcross AJ, Chandler KA, Bingley PJ 2006 Non-specific binding to protein ASepharose and protein G Sepharose in insulin autoantibody assays may be reduced by pre-treatment with glycine or ethanolamine. J Immunol Methods 314:170-173
160. Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ 2010 Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 53:2611-2620
161. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E 2004 Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 114:589-597
162. Schlosser M, Koczwara K, Kenk H, Strebelow M, Rjasanowski I, Wassmuth R, Achenbach P, Ziegler AG, Bonifacio E 2005 In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia 48:1830-1832
163. Achenbach P, Schlosser M, Williams AJ, Yu L, Mueller PW, Bingley PJ, Bonifacio E 2007 Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 122:85-90
164. Achenbach P, Guo LH, Gick C, Adler K, Krause S, Bonifacio E, Colman PG, Ziegler AG 2010 Asimplified method to assess affinity of insulin autoantibodies. Clin Immunol 137:415-421
165. Castaño L, Ziegler AG, Ziegler R, Shoelson S, Eisenbarth GS 1993 Characterization of insulin autoantibodies in relatives of patients with type I diabetes. Diabetes 42:1202-1209
166. Padoa CJ, Crowther NJ, Thomas JW, Hall TR, Bekris LM, Torn C, Landin-Olsson M, Ortqvist E, Palmer JP, Lernmark A, Hampe CS 2005 Epitope analysis of insulin autoantibodies using recombinant Fab. Clin Exp Immunol 140:564-571
167. Devendra D, Galloway TS, Horton SJ, Evenden A, Keller U, Wilkin TJ 2003 The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes. Diabetologia 46:802-809
168. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ 2003 Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26:2871-2875
169. Sabbah E, Savola K, Kulmala P, Veijola R, Vähäsalo P, Karjalainen J, Akerblom HK, Knip M 1999 Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 84:1534-1539
170. Törn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohmé G, Lithner F, Littorin B, Nyström L, Scherstén B, Sundkvist G, Wibell L, Ostman J 2000 Prognostic factors for the course of β cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619-4623
171. Williams AJ, Norcross AJ, Dix RJ, Gillespie KM, Gale EA, Bingley PJ 2003 The prevalence of insulin autoantibodies at the onset of type 1 diabetes is higher in males than females during adolescence. Diabetologia 46:1354-1356
172. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissén M, Ehrnström BO, Forsén B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC 1999 Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48: 150-157
173. Horton V, Stratton I, Bottazzo GF, Shattock M, Mackay I, Zimmet P, Manley S, Holman R, Turner R 1999 Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLADRB1and DQB1genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 42:608-616
174. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC 2007 The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040-17045
175. Füchtenbusch M, Ferber K, Standl E, Ziegler AG 1997 Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 46:1459-1467
176. Slover RH, Eisenbarth GS 1997 Prevention of type 1 diabetes and recurrent β-cell destruction of transplanted islets. Endocr Rev 18:241-258
177. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG 2005 Natural history of type 1 diabetes. Diabetes 54(Suppl 2): S25-S31
178. Ginsberg-Fellner F, Dobersen MJ, Witt ME, Rayfield EJ, Rubinstein P, Notkins AL 1982 HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance in families of children with insulin-dependent diabetes mellitus. Diabetes 31:292-298
179. Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS 1985 First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. N Engl J Med 313:461-464
180. Maclaren NK 1988 Perspectives in diabetes. How, when and why to predict IDDM. Diabetes 37:1591-1594
181. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA 1994 Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43:1304-1310
182. Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazzo GF, Gale EA, Bosi E 1995 Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38:816-822
183. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS 1996 Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933
184. Hawa M, Rowe R, Lan MS, Notkins AL, Pozzilli P, Christie MR, Leslie RD 1997 Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. Diabetes 46:1270-1275
185. Kulmala P, Savola K, Petersen JS, Vähäsalo P, Karjalainen J, Löppönen T, Dyrberg T, Akerblom HK, Knip M 1998 Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 101:327-336
186. Durinovic-Bello I, Jelinek E, Schlosser M, Eiermann T, Boehm BO, Karges W, Marchand L, Polychronakos C 2005 Class III alleles at the insulin VNTR polymorphism are associated with regulatory T-cell responses to proinsulin epitopes in HLA-DR4, DQ8 individuals. Diabetes 54(Suppl 2):S18-S24
187. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, Schaefer JB, Zarghami M, Day HL, Landin-Olsson M, Palmer JP, Janer-Villanueva M, Hood L, Sundkvist G, Lernmark A, Breslow N, Dahlquist G, Blohmé G 2002 Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51: 1346-1355
188. Walter M, Albert E, Conrad M, Keller E, Hummel M, Ferber K, Barratt BJ, Todd JA, Ziegler AG, Bonifacio E 2003 IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity. Diabetologia 46:712-720
189. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, Eisenbarth GS 1996 Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81:4264-4267
190. Genain CP, Zamvil SS 2000 Specific immunotherapy: one size does not fit all. Nat Med 6:1098-1100
191. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA 1994 Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43:1304-1310
192. Bingley PJ 1996 Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Diabetes 45:1720-1728
193. Bonifacio E, Atkinson M, Eisenbarth G, Serreze D, Kay TW, Lee-Chan E, Singh B 2001 International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 50: 2451-2458
194. Yu L, Eisenbarth G, Bonifacio E, Thomas J, Atkinson M, Wasserfall C 2003 The second murine autoantibody workshop: remarkable interlaboratory concordance for radiobinding assays to identify insulin autoantibodies in nonobese diabetic mice. Ann NY Acad Sci 1005:1-12
195. Ziegler AG, Vardi P, Ricker AT, Hattori M, Soeldner JS, Eisenbarth GS 1989 Radioassay determination of insulin autoantibodies in NOD mice. Correlation with increased risk of progression to overt diabetes. Diabetes 38:358-363
196. Melanitou E, Devendra D, Liu E, Miao D, Eisenbarth GS 2004 Early and quantal (by litter) expression of insulin autoantibodies in the nonobese diabetic mice predict early diabetes onset. J Immunol 173:6603-6610
197. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, Fleming SA, Leiter EH, Shultz LD 1996 B Lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig μ null mice. J Exp Med 184:2049-2053
198. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A 1997 B-Cells are required for the initi-ation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46:941-946
199. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM 1998 B Lymphocytes are critical antigenpresenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161:3912-3918
200. Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L 2007 Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117:3857-3867
201. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Mc-Gee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS 2009 Rituximab, B-lymphocyte depletion, and preservation of β-cell function. N Engl J Med 361:2143-2152
202. Yang M, Charlton B, Gautam AM 1997 Development of insulitis and diabetes in B cell-deficient NOD mice. J Autoimmun 10:257-260
203. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, Roep BO 2001 Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 345:1036-1040
204. Greeley SA, Katsumata M, Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, Barker CF, Naji A, Noorchashm H 2002 Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 8:399-402
205. Koczwara K, Ziegler AG, Bonifacio E 2004 Maternal immunity to insulin does not affect diabetes risk in progeny of non obese diabetic mice. Clin Exp Immunol 136:56-59
206. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N 1998 B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 161:1163-1168
207. Noorchashm H, Lieu YK, Noorchashm N, Rostami SY, Greeley SA, Schlachterman A, Song HK, Noto LE, Jevnikar AM, Barker CF, Naji A 1999 I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet β cells of nonobese diabetic mice. J Immunol 163:743-750
208. Silveira PA, Johnson E, Chapman HD, Bui T, Tisch RM, Serreze DV 2002 The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 32:3657-3666
209. Hulbert C, Riseili B, Rojas M, Thomas JW 2001 B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J Immunol 167:5535-5538
210. Acevedo-Suárez CA, Hulbert C, Woodward EJ, Thomas JW 2005 Uncoupling of anergy from developmental arrest in anti-insulin B cells supports the development of autoimmune diabetes. J Immunol 174:827-833
211. Bendelac A, Carnaud C, Boitard C, Bach JF 1987 Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 166:823-832
212. Nagata M, Santamaria P, Kawamura T, Utsugi T, Yoon JW 1994 Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic β-cells in nonobese diabetic mice. J Immunol 152:2042-2050
213. Peterson JD, Haskins K 1996 Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones. Differential requirement for CD8 T-cells. Diabetes 45:328-336
214. Wong FS, Visintin I, Wen L, Flavell RA, Janeway Jr CA 1996 CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 183:67-76
215. Foulis AK, McGill M, Farquharson MA 1991 Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-γ containing cells. J Pathol 165:97-103
216. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR 1985 In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313:353-360
217. Hänninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O 1992 Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 90:1901-1910
218. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M 1993 Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92:2313-2322
219. Somoza N, Vargas F, Roura-Mir C, Vives-Pi M, Fernández-Figueras MT, Ariza A, Gomis R, Bragado R, Martí M, Jaraquemada D 1994 Pancreas in recent onset insulindependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V β usage, and cytokine profile. J Immunol 153:1360-1377
220. Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, Rodriquez-Rilo H, Finegold D, Trucco M 1994 Evidence for superantigen involvement in insulindependent diabetes mellitus aetiology. Nature 371:351-355
221. Sibley RK, Sutherland DE, Goetz F, Michael AF 1985 Recurrent diabetes mellitus in the pancreas iso-and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 53:132-144
222. Boitard C, Chatenoud LM, Debray-Sachs M 1982 In vitro inhibition of pancreatic B cell function by lymphocytes from diabetics with associated autoimmune diseases: a T cell phenomenon. J Immunol 129:2529-2531
223. Naquet P, Ellis J, Tibensky D, Kenshole A, Singh B, Hodges R, Delovitch TL 1988 T cell autoreactivity to insulin in diabetic and related non-diabetic individuals. J Immunol 140:2569-2578
224. Keller RJ 1990 Cellular immunity to human insulin in individuals at high risk for the development of type I diabetes mellitus. J Autoimmun 3:321-327
225. Schloot NC, Roep BO, Wegmann D, Yu L, Chase HP, Wang T, Eisenbarth GS 1997 Altered immune response to insulin in newly diagnosed compared to insulin-treated diabetic patients and healthy control subjects. Diabetologia 40:564-572
226. Lohmann T, Halder T, Engler J, Morgenthaler NG, Khoo-Morgenthaler UY, Schröder S, Seissler J, Scherbaum WA, Kalbacher H 1999 T cell reactivity to DR*0401 and DQ*0302-binding peptides of the putative autoantigen IA-2 in type 1 diabetes. Exp Clin Endocrinol Diabetes 107: 166-171
227. Viglietta V, Kent SC, Orban T, Hafler DA 2002 GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 109:895-903
228. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M 2004 Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113: 451-463
229. Monti P, Scirpoli M, Rigamonti A, Mayr A, Jaeger A, Bonfanti R, Chiumello G, Ziegler AG, Bonifacio E 2007 Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 179:5785-5792
230. Mannering SI, Wong FS, Durinovic-Belló I, Brooks-Worrell B, Tree TI, Cilio CM, Schloot NC, Mallone R, Immunology of Diabetes Society T-Cell Workshop Committee 2010 Current approaches to measuringhumanisletantigen specific T cell function in type 1 diabetes. Clin Exp Immunol 162:197-209
231. Roep BO, Atkinson MA, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA 1999 Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the First International Workshop for Standardization of TCell Assays. J Autoimmun 13:267-282
232. Peakman M, Tree TI, Endl J, van Endert P, Atkinson MA, Roep BO 2001 Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-Cell Assays in Type 1 Diabetes. Diabetes 50: 1749-1754
233. Schloot NC, Meierhoff G, Karlsson FaresjöM, Ott P, Putnam A, Lehmann P, Gottlieb P, Roep BO, Peakman M, Tree T 2003 Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the Third Immunology of Diabetes Society TCell Workshop. J Autoimmun 21:365-376
234. Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Belló I, Cilio CM, Wong FS, Schloot NC 2011 Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 163:33-49
235. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC 2006 Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 55:2588-2594
236. Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM 2009 Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 58:2588-2595
237. Lieberman SM, Takaki T, Han B, Santamaria P, Serreze DV, DiLorenzo TP 2004 Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol 173: 6727-6734
238. Di Lorenzo TP, Peakman M, Roep BO 2007 Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 148:1-16
239. Chang L, Kjer-Nielsen L, Flynn S, Brooks AG, Mannering SI, Honeyman MC, Harrison LC, McCluskey J, Purcell AW 2003 Novel strategy for identification of candidate cytotoxic T-cell epitopes from human preproinsulin. Tissue Antigens 62:408-417
240. Toma A, Haddouk S, Briand JP, Camoin L, Gahery H, Connan F, Dubois-Laforgue D, Caillat-Zucman S, Guillet JG, Carel JC, Muller S, Choppin J, Boitard C 2005 Recognition of a subregion of human proinsulin by class Irestricted T cells in type 1 diabetic patients. Proc Natl Acad Sci USA 102:10581-10586
241. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, Keymeulen B, Pipeleers D, Drijfhout JW, Roep BO 2005 Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 102:18425-18430
242. Hassainya Y, Garcia-Pons F, Kratzer R, Lindo V, Greer F, Lemonnier FA, Niedermann G, van Endert PM 2005 Identification of naturally processed HLA-A2 restricted proinsulin epitopes by reverse immunology. Diabetes 54:2053-2059
243. Frauwirth KA, Thompson CB 2002 Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109: 295-299
244. Shastri N, Cardinaud S, Schwab SR, Serwold T, Kunisawa J 2005 All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 207:31-41
245. Vyas JM, Van der Veen AG, Ploegh HL 2008 The known unknowns of antigen processing and presentation. Nat Rev Immunol 8:607-618
246. Parmentier N, Stroobant V, Colau D, de Diesbach P, Morel S, Chapiro J, van Endert P, Van den Eynde BJ 2010 Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol 11:449-454
247. Dubois-LaForgue D, Carel JC, Bougnères PF, Guillet JG, Boitard C 1999 T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes. J Clin Immunol 19:127-134
248. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A 2001 A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 107:173-180
249. Harrison LC, Honeyman MC, DeAizpurua HJ, Schmidli RS, Colman PG, Tait BD, Cram DS 1993 Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341:1365-1369
250. Hummel M, Durinovic-Bello I, Ziegler AG 1996 Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes. J Autoimmun 9:427-430
251. Durinovic-Bellò I, Hummel M, Ziegler AG 1996 Cellular immune response to diverse islet cell antigens in IDDM. Diabetes 45:795-800
252. Martinuzzi E, Novelli G, Scotto M, Blancou P, Bach JM, Chaillous L, Bruno G, Chatenoud L, van Endert P, Mal-lone R 2008 The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes 57:1312-1320
253. Congia M, Patel S, Cope AP, De Virgiliis S, Sønderstrup G 1998 T Cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc Natl Acad Sci USA 95:3833-3838
254. Durinovic-Belló I, Boehm BO, Ziegler AG 2002 Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity. J Autoimmun 18:55-66
255. Fridlyand LE, Philipson LH 2004 Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic β-cells? Diabetes 53:1942-1948
256. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A 2001 A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 107:173-180
257. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R 2009 No effect of the altered peptide ligand NBI-6024 on β-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32:2036-2040
258. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, Hering BJ, Hafler DA 2005 Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435:224-228
259. Donnelly JJ, Wahren B, Liu MA 2005 DNAvaccines: progress and challenges. J Immunol 175:633-639
260. Fennessy M, Metcalfe K, Hitman GA, Niven M, Biro PA, Tuomilehto J, Tuomilehto-Wolf E 1994 Agene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Childhood Diabetes in Finland (DiMe) Study Group. Diabetologia 37:937-944
261. Demaine AG, Hibberd ML, Mangles D, Millward BA 1995 A new marker in the HLA class I region is associated with the age at onset of IDDM. Diabetologia 38:623-628
262. Robles DT, Eisenbarth GS, Wang T, Erlich HA, Bugawan TL, Babu SR, Barriga K, Norris JM, Hoffman M, Klingensmith G, Yu L, Rewers M 2002 Millennium award recipient contribution. Identification of children with early onset and high incidence of anti-islet autoantibodies. Clin Immunol 102:217-224
263. Marron MP, Graser RT, Chapman HD, Serreze DV 2002 Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Natl Acad Sci USA 99:13753-13758
264. Takaki T, Marron MP, Mathews CE, Guttmann ST, Bottino R, Trucco M, DiLorenzo TP, Serreze DV 2006 HLA-A*0201-restricted T cells from humanized NODmice recognize autoantigens of potential clinical relevance to type 1 diabetes. J Immunol 176:3257-3265
265. Noble JA, Valdes AM, Varney MD, Carlson JA, Moonsamy P, Fear AL, Lane JA, Lavant E, Rappner R, Louey A, Concannon P, Mychaleckyj JC, Erlich HA 2010 HLAclass I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes 59: 2972-2979
266. Martinuzzi E, Lemonnier FA, Boitard C, Mallone R 2008 Measurement of CD8 T cell responses in human type 1 diabetes. Ann NY Acad Sci 1150:61-67
267. Toma A, Laïka T, Haddouk S, Luce S, Briand JP, Camoin L, Connan F, Lambert M, Caillat-Zucman S, Carel JC, Muller S, Choppin J, Lemonnier F, Boitard C 2009 Recognition of human proinsulin leader sequence by class Irestricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes. Diabetes 58:394-402
268. Skowera A, Ellis RJ, Varela-Calviño R, Arif S, Huang GC, Van-Krinks C, Zaremba A, Rackham C, Allen JS, Tree TI, Zhao M, Dayan CM, Sewell AK, Unger WW, Unger W, Drijfhout JW, Ossendorp F, Roep BO, Peakman M 2008 CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 118:3390-3402
269. Mallone R, Martinuzzi E, Blancou P, Novelli G, Afonso G, Dolz M, Bruno G, Chaillous L, Chatenoud L, Bach JM, van Endert P 2007 CD8+ T-cell responses identify β-cell autoimmunity in human type 1 diabetes. Diabetes 56:613-621
270. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, Santamaria P, Tan R 2003 Prediction of spontaneous autoimmune diabetes in NODmice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 111:217-223
271. Enée E, Martinuzzi E, Blancou P, Bach JM, Mallone R, van Endert P 2008 Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J Immunol 180:5430-5438
272. Luo X, Herold KC, Miller SD 2010 Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32:488-499
273. Liu EH, Digon 3rd BJ, Hirshberg B, Chang R, Wood BJ, Neeman Z, Kam A, Wesley RA, Polly SM, Hofmann RM, Rother KI, Harlan DM 2009 Pancreatic β cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a β cell allograft. Diabetologia 52:1369-1380
274. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N 2002 Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 109:131-140
275. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA 2006 CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203:1701-1711
276. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI 2005 Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54:92-99
277. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH 2008 The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181:7350-7355
278. Jiang H, Wu Y, Liang B, Zheng Z, Tang G, Kanellopoulos J, Soloski M, Winchester R, Goldstein I, Chess L 2005 An affinity/avidity model of peripheral Tcell regulation. J Clin Invest 115:302-312
279. Chen W, Zhang L, Liang B, Saenger Y, Li J, Chess L, Jiang H 2007 Perceiving the avidity of T cell activation can be translated into peripheral Tcell regulation. Proc Natl Acad Sci USA 104:20472-20477
280. Wu Y, Zheng Z, Jiang Y, Chess L, Jiang H 2009 The specificity of T cell regulation that enables self-nonself discrimination in the periphery. Proc Natl Acad Sci USA106:534-539
281. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M 2004 Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113: 451-463
282. Tree TI, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, Peakman M 2010 Naturally arising human CD4 T cells that recognize islet autoantigens and secrete IL-10 regulate pro-inflammatory T cell responses via linked suppression. Diabetes 59:1451-1460
283. Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok WW, Nepom GT 2005 Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood 106:2798-2805
284. Dromey JA, Lee BH, Yu H, Young HE, Thearle DJ, Jensen KP, Mannering SI, Harrison LC 2011 Generation and expansion of regulatoryhuman CD4(+) T-cell clones specific for pancreatic islet autoantigens. J Autoimmun 36:47-55
285. Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, Pihoker C, Greenbaum C, Nepom GT, Buckner JH 2009 Functional islet-specific Treg can be generated from CD4+CD25 T cells of healthy and type 1 diabetic subjects. Eur J Immunol 39:612-620
286. Blancou P, Mallone R, Martinuzzi E, Sévère S, Pogu S, Novelli G, Bruno G, Charbonnel B, Dolz M, Chaillous L, van Endert P, Bach JM 2007 Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients. J Immunol 178:7458-7466
287. Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, Eisenbarth GS, Delovitch TL 2001 Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 167:4926-4935
288. Wegmann DR, Norbury-Glaser M, Daniel D 1994 Insulinspecific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 24: 1853-1857
289. Abiru N, Wegmann D, Kawasaki E, Gottlieb P, Simone E, Eisenbarth GS 2000 Dual overlapping peptides recognized by insulin peptide B:9-23 T cell receptor AV13S3 T cell clones of the NOD mouse. J Autoimmun 14:231-237
290. Simone E, Daniel D, Schloot N, Gottlieb P, Babu S, Kawasaki E, Wegmann D, Eisenbarth GS 1997 Tcell receptor restriction of diabetogenic autoimmune NODT cells. Proc Natl Acad Sci USA 94:2518-2521
291. Simone EA, Yu L, Wegmann DR, Eisenbarth GS 1997 T Cell receptor gene polymorphisms associated with antiinsulin, autoimmune T cells in diabetes-prone NOD mice. J Autoimmun 10:317-321
292. Wegmann DR, Gill RG, Norbury-Glaser M, Schloot N, Daniel D 1994 Analysis of the spontaneous T cell response to insulin in NOD mice. J Autoimmun 7:833-843
293. Zekzer D, Wong FS, Ayalon O, Millet I, Altieri M, Shintani S, Solimena M, Sherwin RS 1998 GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 101:68-73
294. Kelemen K, Wegmann DR, Hutton JC 2001 T-Cell epitope analysis on the autoantigen phogrin (IA-2β) in the nonobese diabetic mouse. Diabetes 50:1729-1734
295. Zekzer D, Wong FS, Wen L, Altieri M, Gurlo T, von Grafenstein H, Sherwin RS 1997 Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 46:1124-1132
296. Jasinski JM, Yu L, Nakayama M, Li MM, Lipes MA, Eisenbarth GS, Liu E 2006 Transgenic insulin (B:9-23) Tcell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes 55:1978-1984
297. Du W, Wong FS, Li MO, Peng J, Qi H, Flavell RA, Sherwin R, Wen L 2006 TGF-β signaling is required for the function of insulin-reactive T regulatory cells. J Clin Invest 116: 1360-1370
298. Levisetti MG, Suri A, Petzold SJ, Unanue ER 2007 The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J Immunol 178:6051-6057
299. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW 2010 Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci USA 107:10978-10983
300. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC 1995 Lowavidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3:407-415
301. Mohan JF, Levisetti MG, Calderon B, Herzog JW, Petzold SJ, Unanue ER 2010 Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol 11:350-354
302. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, Adorini L, Jackson DC, Harrison LC 2003 Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 111:1365-1371
303. Halbout P, Briand JP, Bécourt C, Muller S, Boitard C 2002 T Cell response to preproinsulin I and II in the nonobese diabetic mouse. J Immunol 169:2436-2443
304. Wang B, Gonzalez A, Benoist C, Mathis D 1996 The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 26:1762-1769
305. Wicker LS, Leiter EH, Todd JA, Renjilian RJ, Peterson E, Fischer PA, Podolin PL, Zijlstra M, Jaenisch R, Peterson LB 1994 β2-Microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 43:500-504
306. Kay TW, Parker JL, Stephens LA, Thomas HE, Allison J 1996 RIP-β 2-microglobulin transgene expression restores insulitis, but not diabetes, in β 2-microglobulin null nonobese diabetic mice. J Immunol 157:3688-3693
307. Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaria P 1997 Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med 186: 1663-1676
308. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H 1991 Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317
309. Kennedy MK, Tan LJ, Dal Canto MC, Tuohy VK, Lu ZJ, Trotter JL, Miller SD 1990 Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 144:909-915
310. Wong FS, Moustakas AK, Wen L, Papadopoulos GK, Janeway Jr CA 2002 Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 99:5551-5556
311. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA 2006 Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203:2737-2747
312. Ejrnaes M, Videbaek N, Christen U, Cooke A, Michelsen BK, von Herrath M 2005 Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-γ-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, orhoming characteristics. J Immunol 174:2746-2755
313. Wong FS, Siew LK, Scott G, Thomas IJ, Chapman S, Viret C, Wen L 2009 Activation of insulin-reactive CD8 T cells for development of autoimmune diabetes. Diabetes 58: 1156-1164
314. Garza KM, Chan VS, Ohashi PS 2000 T Cell tolerance and autoimmunity. Rev Immunogenet 2:2-17
315. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM 1998 Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188:2163-2173
316. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, Serreze DV, Shabanowitz J, Hunt DF, Nathenson SG, Santamaria P, DiLorenzo TP 2003 Identification of the β cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA 100:8384-8388
317. Achenbach P, Barker J, Bonifacio E 2008 Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 8:87-93
318. Sarantopoulos S, Lu L, Cantor H 2004 Qa-1 restriction of CD8+ suppressor T cells. J Clin Invest 114:1218-1221
319. Tompkins SM, Kraft JR, Dao CT, Soloski MJ, Jensen PE 1998 Transporters associated with antigen processing (TAP)-independent presentation of soluble insulin to α/β T cells by the class Ib gene product, Qa-1(b). J Exp Med 188:961-971
320. Sullivan BA, Kraj P, Weber DA, Ignatowicz L, Jensen PE 2002 Positive selection of a Qa-1-restricted T cell receptor with specificity for insulin. Immunity 17:95-105
321. Reed-Loisel LM, Sullivan BA, Laur O, Jensen PE 2005 An MHC class Ib-restricted TCR that cross-reacts with an MHC class Ia molecule. J Immunol 174:7746-7752
322. Brooks-Worrell B, Palmer JP 2011 Is diabetes mellitus a continuous spectrum? Clin Chem 57:158-161
323. Boitard C, Efendic S, Ferrannini E, Henquin JC, Steiner DF, Cerasi E 2005 A tale of two cousins: type 1 and type 2 diabetes. Diabetes 54(Suppl 2):S1-S3
324. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC 2005 Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206-2212
325. Gale EA 2005 Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 48:2195-2199
326. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM 2005 Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 54(Suppl 2):S62-S67
327. Groop L, Tuomi T, Rowley M, Zimmet P, Mackay IR 2006 Latent autoimmune diabetes in adults (LADA)-more than a name. Diabetologia 49:1996-1998
328. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP 2007 Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 30:2314-2320
329. Bingley PJ, Mahon JL, Gale EA 2008 Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 31:146-150
330. Pang TT, Narendran P 2008 Addressing insulin resistance in type 1 diabetes. Diabet Med 25:1015-1024
331. Li H, Lindholm E, Almgren P, Gustafsson A, Forsblom C, Groop L, Tuomi T 2001 Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 diabetes. J Clin Endocrinol Metab 86:574-582
332. Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa M, Hekkala A, Mattila I, Keskinen P, Yetukuri L, Reinikainen A, Lähde J, Suortti T, Hakalax J, Simell T, Hyöty H, Veijola R, Ilonen J, Lahesmaa R, Knip M, Simell O 2008 Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205:2975-2984
333. Teruya M, Takei S, Forrest LE, Grunewald A, Chan EK, Charles MA 1993 Pancreatic islet function in nondiabetic and diabetic BB rats. Diabetes 42:1310-1317
334. Amrani A, Jafarian-Tehrani M, Mormède P, Durant S, Pleau JM, Haour F, Dardenne M, Homo-Delarche F 1996 Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J Endocrinol 148:139-148
335. Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien YH 2006 Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci USA 103:12475-12480
336. Jansen A, Rosmalen JG, Homo-Delarche F, Dardenne M, Drexhage HA 1996 Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NODmice. Is the prevention of diabetes based on β-cell rest? J Autoimmun 9:341-348
337. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY 2001 Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50:1683-1690
338. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K 1996 Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 39:1306-1312
339. McInerney MF, Rath S, Janeway Jr CA 1991 Exclusive expression of MHC class II proteins on CD45+ cells in pancreatic islets of NOD mice. Diabetes 40:648-651
340. Pujol-Borrell R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D, Adolf GR, Feldmann M 1987 HLA class II induc-tion in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin. Nature 326:304-306
341. Thomas HE, Darwiche R, Corbett JA, Kay TW 1999 Evidence that β cell death in the nonobese diabetic mouse is Fas independent. J Immunol 163:1562-1569
342. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, Trucco M 1997 Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulindependent diabetes mellitus. J Exp Med 186:1193-1200
343. Amrani A, Verdaguer J, Thiessen S, Bou S, Santamaria P 2000 IL-1α, IL-1β, and IFN-γ mark β cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J Clin Invest 105:459-468
344. Pfleger C, Mortensen HB, Hansen L, Herder C, Roep BO, Hoey H, Aanstoot HJ, Kocova M, Schloot NC 2008 Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 57: 929-937
345. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY 2007 Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526
346. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nuñez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LA 2010 Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11:897-904
347. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA 2008 Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31(Suppl 2):S161-S164
348. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA 2009 Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 24:325-331
349. Mandrup-Poulsen T 1996 The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005-1029
350. Mandrup-Poulsen T, Pickersgill L, Donath MY 2010 Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6:158-166
351. Kolb H, Mandrup-Poulsen T 2005 An immune origin of type 2 diabetes? Diabetologia 48:1038-1050
352. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP 1999 Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 48:983-988
353. Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B 2007 T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 56:2110-2115
354. Zavala AV, Fabiano de Bruno LE, Cardoso AI, Mota AH, Capucchio M, Poskus E, Fainboim L, Basabe JC 1992 Cellular and humoural autoimmunity markers in type 2 (noninsulin-dependent) diabetic patients with secondary drug failure. Diabetologia 35:1159-1164
355. Hosszúfalusi N, Vatay A, Rajczy K, Prohászka Z, Pozsonyi E, Horváth L, Grosz A, Gerõ L, Madácsy L, Romics L, Karádi I, Füst G, Pánczél P 2003 Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457
356. Mallone R, Perin PC 2006 Anti-CD38 autoantibodies in type ? diabetes. Diabetes Metab Res Rev 22:284-294
357. Seissler J, de Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA 1998 Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 41:891-897
358. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O'Brien PE, Harrison LC 2010 Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 59:1648-1656
359. Taleb S, Tedgui A, Mallat Z 2010 Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol 10: 197-202
360. Schwartz RH, Bianco AR, Handwerger BS, Kahn CR 1975 Demonstration that monocytes rather than lymphocytes are the insulin-binding cells in preparations of human peripheral blood mononuclear leukocytes: implications for studies of insulin-resistant states in man. Proc Natl Acad Sci USA 72:474-478
361. Helderman JH, Strom TB 1977 Emergence of insulin receptors upon alloimmune T cells in the rat. J Clin Invest 59:338-344
362. Braciale VL, Gavin 3rd JR, Braciale TJ 1982 Inducible expression of insulin receptors on T lymphocyte clones. J Exp Med 156:664-669
363. Helderman JH 1983 T Cell cooperation for the genesis of B cell insulin receptors. J Immunol 131:644-650
364. Stentz FB, Kitabchi AE 2004 Denovo emergence of growth factor receptors in activated human CD4+ and CD8+ T lymphocytes. Metabolism 53:117-122
365. Helderman JH 1981 Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. J Clin Invest 67:1636-1642
366. Kitabchi AE, Stentz FB, Umpierrez GE 2004 Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun 315:404-407
367. Stentz FB, Kitabchi AE 2005 Hyperglycemia-induced activation of human T-lymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species. Biochem Biophys Res Commun 335:491-495
368. Deng HP, Chai JK 2009 The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis. Int Immunopharmacol 9:1251-1259
369. Tian J, Chau C, Kaufman DL 1998 Insulin selectively primes Th2 responses and induces regulatory tolerance to insulin in pre-diabetic mice. Diabetologia 41:237-240
370. Viardot A, Grey ST, Mackay F, Chisholm D 2007 Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology 148:346-353
371. Hunt P, Eardley DD 1986 Suppressive effects of insulin and insulin-like growth factor-1 (IGF1) on immune responses. J Immunol 136:3994-3999
372. McInerney MF, Flynn JC, Goldblatt PJ, Najjar SM, Sherwin RS, Janeway Jr CA 1996 High density insulin receptor-positive Tlymphocytes from nonobese diabetic mice transfer insulitis and diabetes. J Immunol 157:3716-3726
373. Chandra J, Zhivotovsky B, Zaitsev S, Juntti-Berggren L, Berggren PO, Orrenius S 2001 Role of apoptosis in pancreatic β-cell death in diabetes. Diabetes 50(Suppl 1):S44-S47
374. Atkinson MA, Maclaren NK, Luchetta R 1990 Insulitis and diabetes in NODmice reduced by prophylactic insulin therapy. Diabetes 39:933-937
375. Diabetes Prevention Trial-Type 1 Diabetes Study Group 2002 Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685-1691
376. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, Krischer J, Maclaren N 1995 Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-γ transcription. J Clin Invest 95:628-634
377. Karounos DG, Bryson JS, Cohen DA 1997 Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J Clin Invest 100:1344-1348
378. Daniel D, Wegmann DR 1996 Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 93:956-960
379. Hutchings P, Cooke A 1998 Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun 11:127-130
380. Abiru N, Maniatis AK, Yu L, Miao D, Moriyama H, Wegmann D, Eisenbarth GS 2001 Peptide and major histocompatibility complex-specific breaking of humoral tolerance to native insulin with the B9-23 peptide in diabetes-prone and normal mice. Diabetes 50:1274-1281
381. Liu E, Abiru N, Moriyama H, Miao D, Eisenbarth GS 2002 Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B:9-23 peptide without adjuvant. Ann NY Acad Sci 958:224-227
382. Devendra D, Paronen J, Moriyama H, Miao D, Eisenbarth GS, Liu E 2004 Differential immune response to B:9-23 insulin 1 and insulin 2 peptides in animal models of type 1 diabetes. J Autoimmun 23:17-26
383. Liu E, Moriyama H, Abiru N, Paronen J, Devendra D, Finkelman FD, Eisenbarth GS 2004 Preventing peptideinduced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point. J Allergy Clin Immunol 114:607-613
384. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ 2002 Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51:2126-2134
385. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA 2006 Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 63:59-69
386. Gregg RK, Bell JJ, Lee HH, Jain R, Schoenleber SJ, Divekar R, Zaghouani H 2005 IL-10 diminishes CTLA-4 expression on islet-resident T cells and sustains their activation rather than tolerance. J Immunol 174:662-670
387. Tsuji NM, Kosaka A 2008 Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 29:532-540
388. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL 1991 Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88:10252-10256
389. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C 1998 Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 47: 39-44
390. Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG 1999 Insulin in oral immune "tolerance": a oneamino acid change in the B chain makes the difference. J Immunol 163:1833-1838
391. Bergerot I, Arreaza GA, Cameron MJ, Burdick MD, Strieter RM, Chensue SW, Chakrabarti S, Delovitch TL 1999 Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 48:1720-1729
392. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH 1998 A plant-based cholera toxin B subunitinsulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16:934-938
393. Gong Z, Jin Y, Zhang Y 2005 Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes. J Biotechnol 119:93-105
394. Aspord C, Thivolet C 2002 Nasal administration of CTBinsulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 130:204-211
395. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K 1996 Aerosol insulin induces regulatory CD8γδT cells that prevent murine insulin-dependent diabetes. JExpMed 184:2167-2174
396. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, Couper JJ, Colman PG 2004 Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27:2348-2355
397. Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC 2006 Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 176:4608-4615
398. Daniel D, Wegmann DR 1996 Intranasal administration of insulin peptide B:9-23 protects NOD mice from diabetes. Ann NY Acad Sci 778:371-372
399. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, Mathis D, Weissleder R 2011 Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 121:442-445
400. Culina S, Boitard C, Mallone R 14 May 2011 Antigenbased immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol 10.1155/2011/286248
401. Mestas J, Hughes CC 2004 Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731-2738
402. Shah SC, Malone JI, Simpson NE 1989 A randomized trial of intensive insulin therapy in newly diagnosed insulindependent diabetes mellitus. N Engl J Med 320:550-554
403. Rhodes ET, Wolfsdorf JI, Cuthbertson DD, Feldman HA, Ludwig DS 2005 Effect of low-dose insulin treatment on body weight and physical development in children and adolescents at risk for type 1 diabetes. Diabetes Care 28: 1948-1953
404. Carel JC, Landais P, Bougnères P 2002 Therapy to prevent type 1 diabetes mellitus. N Engl J Med 347:1115-1116
405. Coutant R, Carel JC, Aubry V, Lahlou N, Krokowski M, Boitard C, Bougnères PF 2000 Effects of prolonged administration of ultralente insulin on fasting and postbreakfast β-cell function in normal adults. Metabolism 49: 1243-1246
406. Guery JC, Galbiati F, Smiroldo S, Adorini L 1996 Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and β(2)-microglobulin-deficient BALB/c mice. J Exp Med 183:485-497
407. Vølund A, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Sørensen AR, Schlichtkrull J 1991 In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 8:839-847
408. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E 2005 Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28:1068-1076
409. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP; for the DPT-1 and Trial Net Study Groups 24 May 2011 Long-term outcome of individuals treated with oral insulin: Diabetes Prevention Trial-Type 1 (DPT-1) oral insulin trial. Diabetes Care 10.2337/dc11-0523
410. Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Maréchaud R, Bougnères P, Charbonnel B, Saï P 2000 Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356:545-549
411. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A, Spera S, Suraci C, Multari G, Cervoni M, Manca Bitti ML, Matteoli MC, Marietti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G 2000 No effect of oral insulin on residual β-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43:1000-1004
412. Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK 2004 Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 1029:260-277
413. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA 1993 Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259:1321-1324
414. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL 1993 Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727-1730
415. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO 1994 Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 152:4663-4670
416. Waldo FB, van den Wall Bake AW, Mestecky J, Husby S 1994 Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol 72:30-34
417. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O 2008 Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372:1746-1755
418. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, Colman PG, Harrison LC 2011 Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60:1237-1245
419. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P 2010 Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 34: 408-415
420. Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M 2009 Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 155: 156-165
421. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R 2000 Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175
422. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L 2000 Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6:1176-1182